Invossa™ (project name: TissueGene-C) is a cell and gene therapy for the treatment
of osteoarthritis that contains non-transformed chondrocytes and transduced chondrocytes
by the ratio of 3:1. The transduced cell employs ex-vivo gene delivery via a retroviral
transduction which makes overexpression of transforming growth factor β1 (TGF β1).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
